JP2022549335A5 - - Google Patents

Info

Publication number
JP2022549335A5
JP2022549335A5 JP2022519061A JP2022519061A JP2022549335A5 JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5 JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022519061 A JP2022519061 A JP 2022519061A JP 2022549335 A5 JP2022549335 A5 JP 2022549335A5
Authority
JP
Japan
Prior art keywords
psychosis
symptoms
schizophrenia
disorder
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022519061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/052923 external-priority patent/WO2021062307A1/en
Publication of JP2022549335A publication Critical patent/JP2022549335A/ja
Publication of JP2022549335A5 publication Critical patent/JP2022549335A5/ja
Priority to JP2025182550A priority Critical patent/JP7821366B1/ja
Withdrawn legal-status Critical Current

Links

JP2022519061A 2019-09-25 2020-09-25 新規方法 Withdrawn JP2022549335A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182550A JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962906042P 2019-09-25 2019-09-25
US62/906,042 2019-09-25
PCT/US2020/052923 WO2021062307A1 (en) 2019-09-25 2020-09-25 Novel methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182550A Division JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Publications (2)

Publication Number Publication Date
JP2022549335A JP2022549335A (ja) 2022-11-24
JP2022549335A5 true JP2022549335A5 (enExample) 2023-10-02

Family

ID=75166462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022519061A Withdrawn JP2022549335A (ja) 2019-09-25 2020-09-25 新規方法
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182550A Active JP7821366B1 (ja) 2019-09-25 2025-10-29 新規方法

Country Status (4)

Country Link
US (2) US12478623B2 (enExample)
EP (1) EP4034119A4 (enExample)
JP (2) JP2022549335A (enExample)
WO (1) WO2021062307A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
US11408880B2 (en) 2018-05-17 2022-08-09 Northeastern University Lipid-free anchoring of thermophilic bacteriophage G20c portal adapter into solid-state nanopores
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
IL300886A (en) * 2020-09-04 2023-04-01 Intra Cellular Therapies Inc New salts, crystals and co-crystals
WO2025111568A1 (en) * 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
RU2003121304A (ru) 2000-12-20 2005-01-27 Бристол-Маерс Сквибб Компани (Us) Замещенные пиридоиндолы в качестве агонистов и антагонистов серотонина
US6849619B2 (en) 2000-12-20 2005-02-01 Bristol-Myers Squibb Company Substituted pyridoindoles as serotonin agonists and antagonists
TWI312781B (en) 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050058703A1 (en) 2003-08-01 2005-03-17 Chang Robert C. Gelatin capsules
RU2401257C2 (ru) 2004-12-07 2010-10-10 Янссен Фармацевтика Н.В. Новые замещенные тетрациклические производные тетрагидрофурана, пирролидина и тетрагидротиофена
CA2616366A1 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CN101983058A (zh) 2008-02-05 2011-03-02 克莱拉有限公司 缓解抑郁症或改善认知的组合物和方法
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
US8993572B2 (en) 2010-04-22 2015-03-31 Intra-Cellular Therapies, Inc. Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
BR112015005743A2 (pt) 2012-09-14 2017-07-04 Abbvie Deutschland derivados tricíclicos de quinoxalina e quinolina
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
DK3043777T3 (da) 2013-09-10 2020-07-20 Fresh Cut Dev Llc Sublingual buprenorphinspray
KR102967223B1 (ko) 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US9745300B2 (en) 2014-04-04 2017-08-29 Intra-Cellular Therapies, Inc. Organic compounds
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
US11123311B2 (en) 2016-01-05 2021-09-21 The Regents Of The University Of California Methods of treating mental disorders
RU2743513C2 (ru) * 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
IL281050B2 (en) 2016-03-25 2023-04-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
WO2017172811A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2017172784A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
HUE057055T2 (hu) 2016-08-09 2022-04-28 Teva Pharmaceuticals Int Gmbh Lumateperon-ditozilátsó szilárd halmazállapotú formái
JP7013454B2 (ja) 2016-10-12 2022-02-15 イントラ－セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
EP3600325A4 (en) 2017-03-24 2021-01-06 Intra-Cellular Therapies, Inc. UNIQUE COMPOSITIONS AND PROCESSES
WO2018189646A1 (en) 2017-04-10 2018-10-18 Dr. Reddy's Laboratories Limited AMORPHOUS FORM AND SOLID DISPERSIONS OF LUMATEPERONE p-TOSYLATE
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2019023062A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. ORGANIC COMPOUNDS
WO2019067591A1 (en) 2017-09-26 2019-04-04 Intra-Cellular Therapies, Inc. NEW SALTS AND CRYSTALS
CN109867674A (zh) 2017-12-05 2019-06-11 上海度德医药科技有限公司 一种取代的杂环稠合γ-咔啉的新盐及其制备方法和晶型
WO2019178484A1 (en) * 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
BR112020024885A2 (pt) 2018-06-06 2021-03-09 Intra-Cellular Therapies, Inc. Novos sais e cristais
US12144808B2 (en) 2018-08-29 2024-11-19 Intra-Cellular Therapies, Inc. Compositions and methods
AU2019328528B2 (en) * 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof
WO2020182978A1 (en) 2019-03-13 2020-09-17 Sandoz Ag Crystalline salt of a 5-ht2a receptor antagonist
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
WO2021119334A1 (en) 2019-12-11 2021-06-17 Intra-Cellular Therapies, Inc. Organic compound
LT4076461T (lt) 2019-12-19 2026-06-25 Intra-Cellular Therapies, Inc. Lumateperonas, skirtas panaudoti šizofrenijos gydymui
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Similar Documents

Publication Publication Date Title
AU2021202433B2 (en) Neuroactive steroids, compositions, and uses thereof
KR102228598B1 (ko) 최면 진정제의 투여 방법
JP2008531714A (ja) 不安障害の治療用及び／又は予防用の医薬組成物
DE4218572A1 (de) Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US9782404B2 (en) Methods of treating disease-induced ataxia and non-ataxic imbalance
JP2008545793A5 (enExample)
JP2021505575A5 (enExample)
JP7429942B2 (ja) テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミン（ａｎａｖｅｘ２－７３）のエナンチオマーならびにシグマ１レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
EA021962B1 (ru) Способ лечения шизофрении
US20180244623A1 (en) N-methyl-D-aspartate Receptor (NMDAR) Potentiators, Pharmaceutical Compositions, And Uses Related Thereto
JP2021530543A5 (enExample)
ES2963362T3 (es) Métodos de uso de derivados de amidas cíclicas para tratar la esquizofrenia y sus síntomas
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
RU2019132951A (ru) Применение обратного агониста h3r для лечения расстройства сна при сменной работе
Varghese et al. Lamotrigine‐induced toxic epidermal necrolysis in three patients treated for bipolar disorder
TWI494106B (zh) Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途
JP2010509389A (ja) 化学療法剤により誘起された末梢神経毒性の処置に有効なピロロ［１，２−ａ］イミダゾールジオン
US20230064189A1 (en) 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer
ES2969657T3 (es) Tratamiento de trastorno de síndrome postraumático
JPH02212426A (ja) 医薬組成物
HK40009151A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40009154A (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
HK40009154B (en) Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
WO2025019604A2 (en) Proteolysis targeting chimeras for treating neurodegeneration
CN102552266A (zh) 双苄基异喹啉类化合物或其在药学上可接受的盐在制备改善睡眠的药品或保健品中的应用